Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation

Table 3

Selected secondary endpoints.

	Tacrolimus/Sirolimus $N=318$	Tacrolimus/MMF $N=316$
Acute Rejection, Number (%)	82 (25.8)	77 (24.4)
Biopsy confirmed acute rejection, Number (%):	48 ${(15.1)}^{\text{a}}$	39 ${(12.3)}^{\text{a}}$
Spontaneously resolving	1 (0.3)	0 (0.0)
Corticosteroid sensitive	34 (10.7)	32 (10.1)
Corticosteroid resistant	14 (4.4)	8 (2.5)
Resolved with further treatment	12 (3.8)	8 (2.5)
Other	1 (0.3)	0 (0.0)
Histological grade, Number (%):
Mild (Banff I)	30 (9.4)	20 (6.3)
Moderate (Banff II)	17 (5.3)	17 (5.4)
Severe (Banff III)	1 (0.3)	2 (0.6)
Patient $\text{surviva}{\text{l}}^{\text{b}}$, %	99.0	99.0
Graft $\text{surviva}{\text{l}}^{\text{b}}$, %	92.7	93.3

FAS
${}_{}{}^{\text{a}}\text{More}$ than one BCAR episode was reported for some patients.
${}_{}{}^{\text{b}}\text{Kaplan}$-Meier estimates.